Last reviewed · How we verify

NCT06633224

Fatigue and Molecular Mechanisms in Cancer Patients Receiving CCRT

Recruiting now Last updated 16 September 2025
What this trial tests

trial testing Blood Specimen Collection in Cancer in 125 participants. Currently enrolling.

Timeline
27 December 2024
Primary endpoint
1 September 2026
1 September 2027

Quick facts

Lead sponsorUniversity of California, San Francisco
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment125
Start date27 December 2024
Primary completion1 September 2026
Estimated completion1 September 2027
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

University of California, San Francisco

Who can join

18 and older, any sex, with Cancer or Thoracic Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Cancer-related fatigue (CRF) is a significant problem for cancer patients. This prospective, basic science, observational study will evaluate for changes in CRF associated with molecular characteristics prior to, during, and at the completion of non-investigational, standard-of-care, combined chemotherapy and radiation therapy (CCRT) and to develop and assess predictive models for CRF severity.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Blood Specimen Collection

Trials testing the same drug.

Other recruiting trials for Cancer

Currently open trials in the same condition.

Other University of California, San Francisco trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06633224.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing